论文部分内容阅读
丹红注射液由丹参和红花组成,具有活血化瘀、通脉舒络之功,临床广泛应用于全身脏器供血不足的治疗。作为临床急症用药,在心脑血管疾病治疗中发挥了重要作用,但中药注射剂存在潜在的临床风险,不良反应时有发生。通过文献研究,对丹红注射液的基础研究现状进行整理分析,结合现代药剂学研究成果,提出对丹红制剂进行二次开发的思路(鼻腔递药)和可行性分析。
Danhong injection consists of Salvia and safflower, with blood circulation, Tongmai Shulu power, clinical widely used in the treatment of systemic organ insufficiency. As a clinical emergency medication, in the treatment of cardiovascular and cerebrovascular diseases has played an important role, but there is a potential clinical risk injection of Chinese medicine, adverse reactions occur from time to time. Through the literature research, the basic research status of Danhong injection was analyzed. Based on the research results of modern pharmaceutics, the idea of secondary development of Danhong formulation (nasal delivery) and the feasibility analysis were put forward.